Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 54.66% is in line with its 4-year average of 55.57%, around the middle of its 4-year range (49.14%–59.21%).
As of the fiscal period ended Tuesday, March 31, 2026. 1.86% above its 12-month average of 53.66%.
Reported quarterly gross margin; no daily interpolation.
GROSS MARGIN
54.66%
GROSS MARGIN AVG TTM
53.66%
GROSS MARGIN AVG 3Y
55.89%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.86%
CURRENT VS 3Y AVG
-2.20%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
58.51%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-6.58%
vs the sector median at left
Solventum Corporation
Market Cap
$13.83B
Gross Margin
54.66%
TTM Avg
53.66%
3Y Avg
55.89%
5Y Avg
N/A
Market Cap
$13.88B
Gross Margin
64.37%
TTM Avg
63.66%
3Y Avg
64.40%
5Y Avg
64.61%
Market Cap
$12.29B
Gross Margin
67.68%
TTM Avg
69.16%
3Y Avg
69.73%
5Y Avg
70.75%
Market Cap
$11.93B
Gross Margin
30.11%
TTM Avg
33.76%
3Y Avg
35.72%
5Y Avg
36.84%
Market Cap
$11.22B
Gross Margin
64.96%
TTM Avg
65.60%
3Y Avg
66.84%
5Y Avg
66.79%
Market Cap
$16.70B
Gross Margin
28.76%
TTM Avg
30.59%
3Y Avg
29.65%
5Y Avg
29.57%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solventum Corporation (SOLV) | $13.83B | 54.66% | 53.66% | 55.89% | N/A |
| The Cooper Companies, Inc. (COO)vs › | $13.88B | 64.37% | 63.66% | 64.40% | 64.61% |
| DaVita Inc. (DVA)vs › | $15.31B | 31.10% | 29.95% | 30.17% | 30.48% |
| Revvity, Inc. (RVTY)vs › | $12.31B | 51.44% | 50.55% | 50.58% | 52.43% |
| Align Technology, Inc. (ALGN)vs › | $12.29B | 67.68% | 69.16% | 69.73% | 70.75% |
| Baxter International Inc. (BAX)vs › | $11.93B | 30.11% | 33.76% | 35.72% | 36.84% |
| Insulet Corp. (PODD)vs › | $11.65B | 71.01% | 70.71% | 67.87% | 67.39% |
| Bio-Techne Corporation (TECH)vs › | $11.22B | 64.96% | 65.60% | 66.84% | 66.79% |
| Medpace Holdings, Inc. (MEDP)vs › | $16.70B | 28.76% | 30.59% | 29.65% | 29.57% |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.93B | 31.86% | 31.70% | 34.15% | 35.17% |
Gross Margin
54.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 54.66% |
| 2025-12-31 | 49.30% |
| 2025-09-30 | 56.15% |
| 2025-06-30 | 54.37% |
| 2025-03-31 | 53.82% |
| 2024-12-31 | 53.93% |
| 2024-09-30 | 55.96% |
| 2024-06-30 | 54.64% |
| 2024-03-31 | 58.13% |
| 2023-12-31 | 56.88% |
| 2023-09-30 | 58.29% |
| 2023-06-30 | 57.27% |
| 2023-03-31 | 56.54% |
| 2022-12-31 | 49.14% |
| 2022-09-30 | 57.19% |
| 2022-06-30 | 59.21% |
| 2022-03-31 | 59.21% |
